Abstracts

191 – Long-Acting Cabotegravir PrEP Uptake and Persistence in a Large US Healthcare System

Background Long-acting cabotegravir (CAB-LA) was approved as HIV preexposure prophylaxis (PrEP) in the U.S. in December 2021, but data are limited on use in clinical practice. We evaluated CAB-LA uptake and persistence in an integrated healthcare system and compared early CAB-LA adopters to individuals dispensed oral PrEP only. Methods We extracted electronic health records of…

194 – Adherence to F/TAF in Cisgender Women Prevents HIV With Low Risk of Resistance or Diagnostic Delay

Background PURPOSE 1 (NCT04994509) is a Phase 3, double-blind, randomized, controlled trial assessing the efficacy of lenacapavir (LEN) and emtricitabine plus tenofovir alafenamide (F/TAF) for pre-exposure prophylaxis (PrEP) in adolescent girls and young women. Although LEN was 100% efficacious at the primary analysis, F/TAF HIV incidence was similar to the background HIV incidence rate. Case-control…

185 – Low-Cost Counseling Achieves Positive Outcomes for Malawi Men Disengaged From Care: Randomized Trial

Background Men’s suboptimal HIV treatment outcomes hinder epidemic control efforts and jeopardize men’s health. Interventions tailored to men’s unique needs are essential, although rarely tested. We tested the effect of person-centered care interventions on ART engagement among men living with HIV but not in care in Malawi. Methods We conducted an individually randomized control trial…

189 – Systems Analysis and Improvement Approach to Optimize Hypertension Care for People Living With HIV

Background High blood pressure (≥90mmHg/140mmHg) is associated with ~35% of sub-Saharan Africa deaths. In Mozambique, 3% of hypertensive adults achieve controlled blood pressure (BP). Systems engineering strategies applied at the health facility level, like the Systems Analysis and Improvement Approach (SAIA), have been shown effective in improving quality and continuity of health service delivery in…

199 – An Injectable Multipurpose Implant With CAB and MPA for Long-Acting HIV Prevention and Contraception

Background Prevention of HIV and unplanned pregnancies is a leading public health priority for women’s health. Multipurpose prevention technologies (MPTs) capable of delivering long-acting (LA) contraception and HIV prevention are needed. We recently demonstrated in-situ forming implants (ISFIs) in macaques can deliver cabotegravir (CAB) above protective benchmarks (>4 PA-IC90) for more than 5 months. Here, we…

160 – Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening

Background As syphilis rates rise, emergency department (ED) screening has been proposed as an important opportunity for early diagnosis and treatment of syphilis, especially for communities with limited access to care, for whom the ED visit may represent their primary contact with the healthcare system. Given potential increased costs and resources needed for universal screening,…

184 – Most With HIV Viremia Are Not in Care Despite High ART Coverage: A Population-Based Study in Uganda

Background As ART coverage expands in Africa, a greater proportion of persons remaining with viremia are predicted to be HIV serostatus aware and treatment-experienced, potentially reducing the need for population surveillance and community outreach. However, population-level data on the care status of persons with viremia remains limited in African settings achieving “95-95-95” treatment targets.  Methods…

165 – Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV

Background HIV infection significantly increases carcinogenesis following HPV infection. The impact of this relationship on the cervical cancer burden is well documented. Less is known on HPV non-cervical cancers including anal, oropharyngeal, vaginal, vulvar and penile cancers. The World Health Organisation (WHO) aims to vaccinate 90% of girls under 15 against HPV, yet global vaccine…